A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia.

Trial Profile

A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Therapeutic Use
  • Sponsors Intra-Cellular Therapies
  • Most Recent Events

    • 10 Mar 2009 Secondary endpoints 'Sleep efficiency' 'Total sleep time' has been met, according to an Intra-Cellular Therapeutics media release.
    • 10 Mar 2009 Final results have been reported in an Intra Cellular Therapies media release.
    • 13 Jan 2009 Primary endpoints 'Polysomnographic measures' and 'Wake time after sleep onset' have been met, according to an Intra-Cellular therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top